Type
|
Public |
---|---|
Traded as | NYSE: GMED S&P 400 Component |
Industry | Medical Technology |
Founded | 2003 |
Headquarters | Audubon, Pennsylvania |
Key people
|
David C. Paul (Chairman/Co-Founder) David M. Demski (CEO) Anthony L Williams (President) A Brett Murphy (President:Commercial Ops) |
Products | Medical Devices |
Revenue | $544.75 Million (2015) |
Number of employees
|
1,200 (2016) |
Website | http://www.globusmedical.com/ |
Globus Medical, Inc., based in Audubon, PA, is a medical device company focused on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. Globus Medical is a publicly traded company and is listed on the NYSE under the symbol GMED.
The company's products are classified into two categories: Innovative Fusion and Disruptive Technologies. The Innovative Fusion products are uses in cervical, thoracolumbar, sacral, and interbody, corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions. Globus Medical to date has developed a portfolio of spine products, releasing more than 150 products.
January 8, 2014 Globus Medical, Inc announced that it has acquired Excelsius Surgical.The Excelsius system is designed to integrate intra-operative digital imaging with a robotic surgery device to hold patients in place during surgeries "with sub-millimeter accuracy"
October 23, 2014 Globus Medical acquired allograft tissue processor Transplant Technologies of Texas, Ltd. (TTOT). TTOT is a provider of human tissue products including bone allografts, biomaterials, and soft tissue products for spine, orthopedics, sports medicine, dental, and wound care markets.
February 26, 2015, Globus Medical acquired Branch Medical Group, a third party manufacturer of high precision medical devices.
July 26, 2016 ,Globus Medical acquired Alphatec Holdings, Inc international operations and distribution channel for a purchase price of $80 million. As part of the transaction, Globus has also agreed to provide Alphatec a five-year senior secured credit facility of up to $30 million.
Globus Medical ranked #27 in Forbes Lists of America's Best Small Companies (2013)
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-02 | Future report Set alerts | |
Q2 2022 | 2022-08-04 | 0.00 | 0.00 |
Q1 2022 | 2022-05-10 | 0.42 | 0.42 |
Q4 2021 | 2022-02-17 | 0.49 | 0.49 |
Q3 2021 | 2021-11-04 | 0.00 | 0.00 |
Q2 2021 | 2021-08-04 | 0.56 | 0.56 |
Q1 2021 | 2021-05-04 | 0.49 | 0.49 |
Q4 2020 | 2021-02-17 | 0.58 | 0.58 |
Q3 2020 | 2020-10-28 | 0.49 | 0.44 |
Q2 2020 | 2020-08-05 | 0.07 | -0.21 |
2016-06-25 | Reiterated Rating | Piper Jaffray | Overweight | $29.00 |
2016-06-25 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $29.00 |
2016-05-27 | Initiated Coverage | Barclays | Equal Weight | $26.00 |
2016-05-27 | Initiated Coverage | Barclays PLC | Equal Weight | $26.00 |
2016-05-26 | Downgrade | Goldman Sachs | Neutral to Sell | $21.00 |
2016-05-26 | Downgrade | Goldman Sachs Group Inc. | Neutral to Sell | $21.00 |
2016-05-16 | Downgrade | Goldman Sachs | Neutral to Sell | $26.00 to $21.00 |
2016-05-04 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
2016-05-04 | Reiterated Rating | Brean Capital | Buy | |
2016-05-04 | Reiterated Rating | Leerink Swann | Buy | |
2016-05-04 | Reiterated Rating | Oppenheimer | Buy | $29.00 |
2016-05-04 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | $29.00 |
2016-02-25 | Reiterated Rating | Canaccord Genuity | Buy | $30.00 |
2016-02-25 | Reiterated Rating | Leerink Swann | Outperform | $32.00 to $29.00 |
2016-02-24 | Reiterated Rating | William Blair | Outperform | |
2016-01-08 | Downgrade | Bank of America | Buy to Underperform | $28.00 |
2016-01-08 | Reiterated Rating | JMP Securities | Buy | |
2016-01-08 | Reiterated Rating | Leerink Swann | Buy | |
2016-01-08 | Downgrade | Bank of America Corp. | Buy to Underperform | $28.00 |
2016-01-07 | Boost Price Target | Leerink Swann | Outperform | $31.00 to $32.00 |
2015-11-13 | Reiterated Rating | Canaccord Genuity | Buy | |
2015-11-13 | Initiated Coverage | Oppenheimer | Buy | |
2015-11-04 | Reiterated Rating | Brean Capital | Buy | |
2015-11-04 | Boost Price Target | Leerink Swann | Outperform | $28.00 to $29.00 |
2015-11-04 | Reiterated Rating | Canaccord Genuity | Buy | $35.00 |
2015-10-19 | Lower Price Target | Leerink Swann | Outperform | $32.00 to $28.00 |
2015-10-15 | Reiterated Rating | Morgan Stanley | Overweight | $32.00 |
2015-09-28 | Initiated Coverage | Morgan Stanley | Overweight | $32.00 |
2015-09-14 | Initiated Coverage | Morgan Stanley | Overweight | $32.00 |
2015-08-27 | Lower Price Target | Goldman Sachs | $27.00 to $26.00 | |
2015-08-03 | Boost Price Target | Leerink Swann | Outperform | $30.00 to $32.00 |
2015-07-27 | Reiterated Rating | Brean Capital | Buy | $33.00 |
2015-05-20 | Set Price Target | Canaccord Genuity | Buy | $31.00 |
2015-05-06 | Reiterated Rating | Canaccord Genuity | Buy | $31.00 |
2015-05-06 | Reiterated Rating | Oppenheimer | Outperform | $28.00 |
2015-05-06 | Boost Price Target | Brean Capital | Buy | $30.00 to $33.00 |
2015-04-26 | Reiterated Rating | Canaccord Genuity | Buy | $31.00 |
2015-04-23 | Set Price Target | Brean Capital | Buy | $30.00 |
2015-04-14 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
2015-04-14 | Initiated Coverage | Wells Fargo | Outperform | |
2015-03-20 | Set Price Target | Canaccord Genuity | Buy | $31.00 |
2015-03-17 | Set Price Target | Oppenheimer | Buy | $28.00 |
2015-03-02 | Boost Price Target | WallachBeth Capital | Buy | $26.00 to $30.00 |
2015-02-27 | Boost Price Target | Leerink Swann | Outperform | $28.00 to $29.00 |
2015-02-26 | Boost Price Target | Brean Capital | Buy | $28.00 to $30.00 |
2015-02-26 | Boost Price Target | Canaccord Genuity | Buy | $28.00 to $31.00 |
2015-01-26 | Set Price Target | Canaccord Genuity | Buy | $28.00 |
2015-01-07 | Boost Price Target | JMP Securities | Market Outperform | $25.00 to $29.00 |
2015-01-07 | Boost Price Target | Oppenheimer | Outperform | $24.00 to $26.00 |
2015-01-07 | Initiated Coverage | Piper Jaffray | Overweight | $28.00 |
2014-11-11 | Initiated | Brean Capital | Buy | $28 |
2014-11-10 | Initiated Coverage | Brean Capital | Buy | $28.00 |
2014-10-31 | Reiterated Rating | Canaccord Genuity | Buy | $24.00 to $28.00 |
2014-09-11 | Boost Price Target | Piper Jaffray | Top Pick | $28.00 |
2014-09-11 | Initiated Coverage | JMP Securities | Outperform | $25.00 |
2014-08-19 | Initiated Coverage | Gabelli | Buy | $30.00 |
2014-08-06 | Upgrade | WallachBeth | Hold to Buy | |
2014-08-06 | Reiterated Rating | Oppenheimer | Outperform | $28.00 to $24.00 |
2014-08-06 | Upgrade | WallachBeth Capital | Hold to Buy | $27.00 to $24.00 |
2014-08-06 | Lower Price Target | Piper Jaffray | $28.00 to $26.00 | |
2014-08-06 | Lower Price Target | Canaccord Genuity | Buy | $27.00 to $24.00 |
2014-04-30 | Lower Price Target | Canaccord Genuity | Buy | $28.00 to $27.00 |
2014-02-27 | Downgrade | WallachBeth | Buy to Hold | $23 to $27 |
2014-02-27 | Boost Price Target | Piper Jaffray | $26.00 to $28.00 | |
2014-02-27 | Boost Price Target | Leerink Swann | $26.00 to $28.00 | |
2014-02-27 | Downgrade | WallachBeth Capital | Buy to Hold | $23.00 to $27.00 |
2014-01-22 | Boost Price Target | Canaccord Genuity | Buy | $26.00 to $28.00 |
2013-10-31 | Boost Price Target | Piper Jaffray | Overweight | $22.00 to $25.00 |
2013-10-31 | Boost Price Target | Canaccord Genuity | Buy | $24.00 to $26.00 |
2013-10-14 | Downgrade | Goldman Sachs | Buy to Neutral | $19.00 to $18.00 |
2013-06-24 | Reiterated | Oppenheimer | Outperform | $18 to $19 |
2012-12-14 | Reiterated | Canaccord Genuity | Buy | $20 to $22 |
2012-08-28 | Initiated | William Blair | Outperform | |
2012-08-28 | Initiated | Oppenheimer | Outperform | $18 |
2012-08-28 | Initiated | Canaccord Genuity | Buy | $20 |
2016-06-25 | Reiterated Rating | Piper Jaffray | Overweight | $29.00 |
2016-06-25 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $29.00 |
2016-05-27 | Initiated Coverage | Barclays | Equal Weight | $26.00 |
2016-05-27 | Initiated Coverage | Barclays PLC | Equal Weight | $26.00 |
2016-05-26 | Downgrade | Goldman Sachs | Neutral to Sell | $21.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In GMED 270 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 7.26M |
Vanguard Group, Inc | 7.19M |
HENDERSON GROUP PLC | 7.04M |
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 4.56M |
BlackRock Fund Advisors | 4.39M |
WELLINGTON MANAGEMENT CO LLP | 3.65M |
STATE STREET CORP | 2.19M |
BlackRock Institutional Trust Company, N.A. | 2.14M |
Champlain Investment Partners, LLC | 2.04M |
Capital Research Global Investors | 2.00M |
JANUS CAPITAL MANAGEMENT LLC | 1.98M |
Invesco Ltd. | 1.76M |
GANNETT WELSH & KOTLER | 1.58M |
AXA | 1.51M |
GENEVA CAPITAL MANAGEMENT LLC | 1.41M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
GOLDMAN SACHS GROUP INC | 8.10% (7643526) | AHS / AMBR / ARMK / ARX / BNFT / CIE / EBIX / EDMC / EIGI / ENLK / ESNT / GFF / GMED / GS / H / HABT / KMI / LACO / LLNW / MGI / MRC / PNRG / TIPT / TTOO / ZINC / ZMH / |
GOLDMAN SACHS PRIVATE EQUITY PARTNERS 2004 OFFSHORE HOLDINGS, L.P. | 8.10% (7643526) | GMED / |
Davidar David D Vice President, Operations | 0.75% (709775) | GMED / |
Paul David C Chief Executive Officer | 0.65% (612712) | GMED / |
Demski David M President and COO | 0.16% (148855) | GMED / |
WHEELER KURT | 0.05% (44319) | GMED / ZGNX / |
Murphy A Brett Executive VP, US Sales | 0.04% (35217) | GMED / |
LIPTAK ROBERT | 0.03% (26159) | GMED / |
Payne Steven Chief Accounting Officer | 0.03% (23847) | GMED / |
Williams Anthony L Senior VP of Bus. Devel. & GC | 0.02% (15000) | GMED / |